As India is seeing a gradual increase in daily cases with the unprecedented surge Indian based vaccine companies are ramping up the vaccine production for Phase 3 of the vaccination drive.
Recognising the enormous challenges to the healthcare system Bharat Biotech announced to cut the COVAXIN vaccine prices from Rs 600 to Rs 400 for state government.
Bharat Biotech in its press release informed that “deeply concerned with the critical pandemic circumstances that India is facing at this time”.
“Recognizing the enormous challenges to the public health care system, we have made COVAXIN available to State Governments at a price of Rs. 400/dose” reads the press release.
We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally-intensive BSL-3 manufacturing facilities (the first of its kind in our country) and clinical trials.
We wish to champion “Innovation in India” and our commitment to public health is absolute!
For the last year, Team Bharat Biotech has been fearlessly handling Live SARS-CoV-2 virus strains, tirelessly working round-the-clock while overcoming many challenges given the uncertainty of the pandemic.
With the greater part of the organization’s facilities and resources being diverted to COVID-19 vaccines, we continue to work towards offering superior COVID-19 vaccines and sincerely wish that this gesture enables our country towards a faster recovery.
We offer our prayers to all the citizens of India and wish them safety and health! A day before Serum Institute of India cut the price of ‘COVISHIELD’ vaccine for state from Rs 400 to Rs 300.
